the aid library

LIST OPTIONS

Filter

5862

The Global Burden of Disease Study at 30 years

Murray, C.J.L. nature medicine (2022) CC

The Global Burden of Disease Study (GBD) began 30 years ago with the goal of providing timely, valid and relevant assessments of critical health outcomes. Over this period, the GBD has become progressively more granular. The latest iteration provides assessments of thousands of outcomes for diseases... more

Medicines for HIV, viral hepatitis and sexually transmitted infections in low- and middle- income countries: forecasts of global demand for 2022–2026

World Health Organization WHO (2024) C_WHO

For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries. The purpose of this rep... more

Prevention of Cardiovascular Disease: Guidelines for assessment and management of cardiovascular risk

World Health Organization WHO (2007) C_WHO

Cardiovascular disease is a major cause of disability and premature death throughout the world, and contributes substantially to the escalating costs of health care. The underlying pathology is atherosclerosis, which develops over many years and is usually advanced by the time symptoms occur, genera... more

Moving to a strong(er) community health system: analysing the role of community health volunteers in the new national community health strategy in Malawi

Angwenyi, V.; Aantjes, C.; Kondowe, K. et al. BMJ Global Health (2018) CC

Since the Alma Ata Declaration in 1978, community health volunteers (CHVs) have been at the forefront, providing health services, especially to underserved communities, in low-income countries. However, consolidation of CHVs position within formal health systems has proved to be complex and continue... more

Countdown to 2023: WHO report on global trans-fat elimination 2022 WHO

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

This fourth annual report monitors global progress towards the 2023 target for global elimination of industrially produced trans-fatty acids (TFA), highlighting achievements during the past year (October 2021 – September 2022). Countries are responding to the World Health Organization (WHO) call t... more

Advancing the global agenda on prevention and control of noncommunicable diseases 2000 to 2020

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

This document highlights landmarks and key milestones in the development and implementation of the global agenda for noncommunicable diseases (NCDs) over the last two decades. It summarizes where the world was in 2000, where it is in 2022, and where the world wants to be in terms of NCD prevention a... more

Integrating the prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis, and sexual and reproductive health programmes

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The WHO document "Integrating the prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis, and sexual and reproductive health programmes: implementation guidance" provides a framework for integrating noncommunicable diseases (NCDs) into existing health programs for HIV/AIDS, tub... more

The efects of extreme heat on human health in tropical africa

Kunda J., Gosling S., Foody G. et al. (2024) C2

This review examines high-quality research evidence that synthesises the efects of extreme heat on human health in tropical Africa. Web of Science (WoS) was used to identify research articles on the efects extreme heat, humidity, Wet-bulb Globe Temperature (WBGT), apparent temperature, wind, Heat ... more

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors 2023

World Health Organization WHO (2023) C_WHO

The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys... more

Pathogenesis of chronic obstructive pulmonary disease: An African perspective

Allwood, B.; Calligaro, G. South African Medical Journal (SAMJ) (2015) CC2

The article discusses the significant impact of chronic obstructive pulmonary disease (COPD) as a global health issue, with cigarette smoking as the main risk factor. However, in developing countries, the causes of COPD are often multifactorial, involving environmental tobacco smoke, biomass fuel sm... more

Medical device donations: considerations for solicitation and provision. Second edition

World Health Organization WHO (2024) CC

Medical devices are used for the prevention, diagnosis and treatment of illness and diseases and for rehabilitation. WHO developed guidance on medical device donation in 2011, which has been now reviewed, with new evidence, new references on considerations for medical device solicitation and provisi... more

Health statistics in the Western Pacific Region 2023: monitoring health for the SDGs

World Health Organisation (WHO) (2024) CC

Health Statistics in the Western Pacific Region 2023: Monitoring health for the SDGs is the third biennial report providing an overview of the progress of the World Health Organization (‎WHO)‎ Western Pacific Region towards the health-related Sustainable Development Goal (‎SDG)‎ targets. Thi... more

WHO Country Cooperation Strategy 2017 -2022 Malawi

World Health Organization WHO (2022) CC2

The Country Cooperation Strategy is the World Health Organization (WHO)’s reference for country work guiding planning and resource allocation through alignment with national health priorities and harmonization with other development partners. It clarifies roles and functions of WHO in supporting t... more

This 4 th Edition of the Malawi Guidelines for Clinical Management of HIV in Children and Adults will be implemented from July 2018

Ministry of Health and Population, Malawi (2018) CC2

This document defines the framework for Malawi’s National HIV Programs. Considering public health benefits and risks, as well as funding and resource implications, deviations from these guidelines are not supported by the Ministry of Health.

Sexual, reproductive, maternal, newborn, child and adolescent health: report on the 2023 policy survey

World Health Organisation (WHO) (2024) C_WHO

Evidence- and rights-based national policies, guidelines and legislation play a key role in improving sexual, reproductive, maternal, newborn, child and adolescent health (SRMNCAH), framing the enabling environment for equitable provision and accessibility of quality services. The SRMNCAH policy sur... more

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more